Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201403 | 0.65 | — | — | |
| SCHEMBL9852284 | 0.65 | SMN1; SMN2 (0.53) | MAPTALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL155142 | 0.65 | RAB9A (0.57) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL11831966 | 0.65 | POLB (0.44) | MAPTALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL14960416 | 0.64 | KMT2A (0.59) | ALDH1A1HPGDNPC1RAB9ALMNA | |
| SCHEMBL629408 | 0.64 | CA1 (0.62) | MAPTALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL2070478 | 0.64 | TSHR (0.34) | MAPTALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL48394 | 0.64 | MAPT (0.66) | MAPTALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL989627 | 0.64 | — | — | |
| SCHEMBL19994395 | 0.64 | MAPT (0.66) | MAPTALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168322-A1 | NOVEL STAT3 INHIBITORS IDENTIFIED BY STRUCTURE-BASED VIRTUAL SCREENING INCORPORATING SH2 DOMAIN FLEXIBILITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-02 | — | — | US | claimed |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | claimed |
| WO-2020018944-A1 | NOVEL STAT3 INHIBITORS IDENTIFIED BY STRUCTURE-BASED VIRTUAL SCREENING INCORPORATING SH2 DOMAIN FLEXIBILITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-01-23 | — | — | WO | claimed |
| WO-2020008317-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-09 | — | — | WO | claimed |
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | claimed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | claimed |
| EP-1235595-B1 | INTEGRIN-MEDIATED DRUG TARGETING | ALBERS MARKUS (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | claimed |
| EP-0300526-A2 | Antiviral pharmaceutical compositions containing cyclodextrins | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | claimed |
| EP-0093591-B1 | SELECTIVE SULFONATION PROCESS | ELI LILLY AND COMPANY (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0093591-A1 | Selective sulfonation process | ELI LILLY AND COMPANY (US) | 1983-11-09 | — | — | EP | claimed |
| US-4401817-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-30 | — | — | US | claimed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | claimed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | claimed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | claimed |
| US-4136253-A | ANTIBIOTICS | PFIZER INC. (US) | 1979-01-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168322-A1 | NOVEL STAT3 INHIBITORS IDENTIFIED BY STRUCTURE-BASED VIRTUAL SCREENING INCORPORATING SH2 DOMAIN FLEXIBILITY | JAK2, STAT3, STAT5B | MAPT 4449/4885ALDH1A1 3826/4885HPGD 4109/4885 |
| US-20210253562-A1 | ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, FFAR3, PTGES3 | MAPT 4878/4885ALDH1A1 3778/4885HPGD 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.